<DOC>
	<DOCNO>NCT00055601</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy ( RT ) use high-energy x-rays damage tumor cell . It yet know regimen combination chemotherapy plus radiation therapy without surgery effective treat bladder cancer . PURPOSE : Randomized phase II trial study effectiveness two combination chemotherapy regimens radiation therapy without radical cystectomy treat patient stage II stage III bladder cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Estimate safety tolerability induction paclitaxel , cisplatin , radiotherapy fluorouracil , cisplatin , radiotherapy follow consolidation chemoradiotherapy radical cystectomy adjuvant gemcitabine , paclitaxel , cisplatin patient operable stage II III bladder cancer . - Estimate efficacy regimen , term complete response , patient undergo prior transurethral resection ( TUR ) . - Estimate efficacy regimens TUR , term preserve native tumor-free bladder 5 year therapy , patient . - Estimate function preserve bladder patient treat regimen TUR . - Determine value tumor histopathologic , molecular genetic , DNA content parameter possible prognostic factor initial tumor response recurrence-free survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord T stage ( T2 v T3/T4 ) . Patients randomize one two treatment arm . - Induction therapy ( week 1-3 ) : - Arm I : Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 cisplatin IV 1 hour day 1-3 , 8-10 , 15-17 . Patients also receive pelvic radiotherapy twice daily day 1-5 , 8-12 , 15-17 . - Arm II : Patients receive fluorouracil IV 24 hour day 1-3 15-17 cisplatin IV 1 hour day 1-3 , 8-10 , 15-17 . Patients also receive pelvic radiotherapy arm I . Patients arm achieve complete response induction therapy proceed consolidation therapy week 8 . Patients operable pT1 bad tumor response proceed radical cystectomy week 9 . - Consolidation therapy ( week 8 9 ) : - Arm I : Patients receive paclitaxel IV 1 hour day 1 8 cisplatin IV 1 hour day 1 , 2 , 8 , 9 . Patients also receive pelvic radiotherapy twice daily day 1-5 8-10 . - Arm II : Patients receive 5-FU IV 24 hour day 1-3 8-10 cisplatin arm I . Patients also receive radiotherapy arm I . - Adjuvant chemotherapy ( week 21-33 17-29 ) : Beginning 12 week consolidation therapy 8 week radical cystectomy , patient receive gemcitabine IV 30-60 minute , paclitaxel IV 1 hour , cisplatin IV 1 hour day 1 8 . Treatment repeat every 3 week 4 course . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 96 patient ( 48 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm operable primary muscle invasive bladder cancer T2T4a , NX N0 , M0 ( stage II III ) Must adequate function bladder Must undergone prior transurethral resection bladder tumor within past 8 week No evidence tumorrelated hydronephrosis No evidence distant metastasis histologically cytologically confirm lymph node metastases Patients involvement prostatic urethra transitional cell cancer visibly completely resect allow No evidence stromal invasion prostate PATIENT CHARACTERISTICS : Age Not specify Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Hemoglobin least 10 g/dL White blood cell ( WBC ) count least 4,000/mm^3 Absolute neutrophil count least 1,800/mm^3 Platelet count least 100,000/mm^3 Hepatic Serum bilirubin great 2.0 mg/dL Renal Serum creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min NOTE : If creatinine clearance great 60 mL/min , creatinine great 1.8 mg/dL allow discretion study chair Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except nonmelanoma skin cancer , stage T1a prostate cancer , carcinoma situ cervix Must able tolerate systemic chemotherapy pelvic radiotherapy radical cystectomy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy No prior pelvic radiotherapy Surgery See Disease Characteristics Other No concurrent drug potential nephrotoxicity ototoxicity ( e.g. , aminoglycosides )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
</DOC>